Edition:
India

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

90.48EUR
23 Oct 2020
Change (% chg)

€-0.24 (-0.26%)
Prev Close
€90.72
Open
€90.58
Day's High
€91.14
Day's Low
€90.06
Volume
148,668
Avg. Vol
328,366
52-wk High
€114.45
52-wk Low
€60.18

Latest Key Developments (Source: Significant Developments)

UCB Signs Agreement To Acquire New Campus In UK
Friday, 16 Oct 2020 

Oct 16 (Reuters) - UCB SA ::AGREEMENT TO ACQUIRE A NEW LEADING-EDGE CAMPUS IN UK.ACQUISITION OF SITE ANTICIPATED TO BE COMPLETED IN NOVEMBER 2020.47-ACRE (19 HECTARE) CAMPUS WILL BE ACQUIRED FROM ELI LILLY AND COMPANY LIMITED .THIS NEW UK SITE WILL NOT ONLY SUPPORT OUR AMBITIONS FOR FUTURE DRUG DISCOVERY BUT WILL BE WELL-PLACED TO ENABLE US TO ACHIEVE OUR 2030-CEO.  Full Article

UCB And Aetion Announce Agreement To Enhance Real-World Evidence Generation
Wednesday, 7 Oct 2020 

Oct 7 (Reuters) - Ucb SA ::UCB AND AETION ANNOUNCE AGREEMENT TO ENHANCE REAL-WORLD EVIDENCE GENERATION TO ADVANCE VALUE-BASED CONTRACTS.  Full Article

UCB Says Stefan Oschmann Will Be Proposed As Chair Of Board Of Directors
Friday, 2 Oct 2020 

Oct 2 (Reuters) - Ucb SA ::ON APRIL 29, 2021, EVELYN DU MONCEAU WILL HAVE REACHED THE STATUTORY AGE LIMIT AND WILL STEP DOWN AS CHAIR AND DIRECTOR OF THE BOARD OF UCB SA/NV.STEFAN OSCHMANN, WHO IS COMPLETING HIS SUCCESSFUL TENURE AS CEO OF MERCK BY END OF APRIL 2021 WILL BE PROPOSED AS SUCCESSOR TO EVELYN DU MONCEAU IN ROLE OF CHAIR OF UCB'S BOARD OF DIRECTORS.STEFAN OSCHMANN WILL BE AN INDEPENDENT BOARD MEMBER.  Full Article

UCB Presents Phase 3 Data On Vimpat, Says Study Met Primary And Secondary Endpoints
Monday, 31 Aug 2020 

Aug 31 (Reuters) - UCB SA ::PHASE 3 DATA ON VIMPAT® (LACOSAMIDE) IN PRIMARY GENERALIZED TONIC-CLONIC SEIZURES PUBLISHED IN JOURNAL OF NEUROLOGY, NEUROSURGERY & PSYCHIATRY.LACOSAMIDE WAS GENERALLY TOLERATED BY PATIENTS ENROLLED IN STUDY.STUDY MET PRIMARY AND SECONDARY ENDPOINTS OF SIGNIFICANTLY LOWERING RISK OF DEVELOPING A SECOND PRIMARY GENERALIZED TONIC-CLONIC SEIZURE (PGTCS) DURING A 24-WEEK TREATMENT AND A SIGNIFICANTLY HIGHER RATE OF FREEDOM FROM PGTCS DURING TREATMENT PERIOD COMPARED WITH PLACEBO.VIMPAT® IS CURRENTLY NOT APPROVED FOR PGTCS IN ANY COUNTRY IN WORLD.REGULATORY REVIEWS, BASED, IN PART, ON THESE DATA, ARE CURRENTLY UNDERWAY IN THE U.S., EU, JAPAN, AND AUSTRALIA.  Full Article

UCB Completes 2020 Share Repurchase Program
Monday, 10 Aug 2020 

Aug 10 (Reuters) - Ucb SA ::IN FRAMEWORK OF SHARE REPURCHASE PROGRAM 2020, UCB REPURCHASED 178,242 SHARES.SHARE REPURCHASE PROGRAM 2020 HAS BEEN COMPLETED.  Full Article

UCB: EMA Approves Label Extension For Cimzia
Wednesday, 5 Aug 2020 

Aug 5 (Reuters) - Ucb SA ::(EMA) HAS APPROVED A LABEL EXTENSION FOR CIMZIA® (CERTOLIZUMAB PEGOL).EXTENTIONS APPROVED FOR USE IN ADULT PATIENTS WITH AXSPA AT A REDUCED MAINTENANCE DOSE OF 200 MG EVERY FOUR WEEKS (Q4W).APPROVAL MAKES CIMZIA ONLY BIOLOGIC IN EUROPE WITH A DOSE REDUCTION OPTION IN ITS LABEL FOR PATIENTS IN BROAD AXSPA POPULATION.  Full Article

Financiere De Tubize H1 Profit For Period In Belgian Standards At EUR 83.4 Mln
Monday, 27 Jul 2020 

July 27 (Reuters) - FINANCIERE DE TUBIZE SA ::2020 HALF-YEAR FINANCIAL REPORT.DIVIDEND RECEIVED FROM UCB: EUR 84.4 MILLION.H1 PROFIT FOR PERIOD WHEN APPLYING BELGIAN ACCOUNTING FRAMEWORK: EUR 83.4 MILLION.H1 PROFIT FOR PERIOD WHEN APPLYING INTERNATIONAL STANDARD IAS 34: EUR 129.7 MILLION.PARTICIPATING INTEREST IN UCB UNCHANGED AT 35.00%.DECREASING BANK DEBT FROM EUR 86.5 MILLION AT 31 DECEMBER 2019 TO EUR 32.0 MILLION AT 30 JUNE 2020.  Full Article

UCB H1 Adjusted EBITDA Rises To EUR 783 Million, 2020 Outlook Confirmed
Monday, 27 Jul 2020 

July 27 (Reuters) - Ucb SA ::H1 REVENUE INCREASED TO EUR 2.6 BILLION AND NET SALES TO EUR 2.5 BILLION.FINANCIAL OUTLOOK FOR 2020 CONFIRMED.H1 UNDERLYING PROFITABILITY (ADJUSTED. EBITDA) WAS EUR 783 MILLION (+8%, 0% CER) OR A RATIO OF 30%.NET FINANCIAL EXPENSES INCREASED TO EUR 61 MILLION FROM EUR 53 MILLION, DUE TO DEBT FINANCING OF RA PHARMA ACQUISITION.H1 CORE EARNINGS PER SHARE REACHED EUR 2.77.  Full Article

UCB Says Phase 3b BE RADIANT Study Met Primary Endpoint
Friday, 24 Jul 2020 

July 24 (Reuters) - UCB SA ::PHASE 3B BE RADIANT STUDY MET ITS PRIMARY ENDPOINT AND ALL RANKED SECONDARY ENDPOINTS.BIMEKIZUMAB DEMONSTRATED SUPERIORITY TO COSENTYX[®] (SECUKINUMAB) FOR PASI 100 AT WEEK 16 AND PASI 100 AT WEEK 48.POSITIVE RESULTS CONFIRM THE SPEED, DEPTH AND DURABILITY OF RESPONSE SEEN WITH BIMEKIZUMAB IN THREE PREVIOUS PHASE 3 STUDIES, AND REINFORCE THE IMPORTANCE OF SELECTIVELY INHIBITING IL-17F, IN ADDITION TO IL-17A.SAFETY AND EFFICACY OF BIMEKIZUMAB HAVE NOT BEEN ESTABLISHED AND IT IS NOT APPROVED BY ANY REGULATORY AUTHORITY WORLDWIDE..  Full Article

UCB Canada Says Data From Phase 3 Be Vivid, Be Ready Studies Show Bimekizumab-Treated Patients With Psoriasis Showed Significant Skin Clearance At Week 16
Monday, 22 Jun 2020 

June 22 (Reuters) - UCB CANADA::UCB CANADA- DATA FROM PHASE 3 BE VIVID, BE READY STUDIES SHOW BIMEKIZUMAB-TREATED PATIENTS WITH PSORIASIS SHOWED SIGNIFICANT SKIN CLEARANCE AT WEEK 16.UCB CANADA - MAJORITY OF PATIENTS IN BE READY, BE VIVID STUDIES ACHIEVED RAPID AND LASTING SKIN CLEARANCE.UCB CANADA- SAFETY AND EFFICACY OF BIMEKIZUMAB HAVE NOT BEEN ESTABLISHED.UCB CANADA- IN BE VIVID, PATIENTS TREATED WITH BIMEKIZUMAB 320 MG EVERY Q4W SHOWED SIGNIFICANTLY SUPERIOR SKIN CLEARANCE THAN THOSE RECEIVING PLACEBO.UCB CANADA - FULL RESULTS FROM PLACEBO AND ADALIMUMAB COMPARATOR BE SURE STUDY TO BE PRESENTED AT A FUTURE SCIENTIFIC CONGRESS.UCB CANADA- PHASE 3 TRIALS OF BIMEKIZUMAB IN PSORIATIC ARTHRITIS, AXIAL SPONDYLOARTHRITIS, HIDRADENITIS SUPPURATIVA ARE ALSO UNDERWAY.  Full Article

BRIEF-UCB And Ferring Pharmaceuticals Announce Co-Promotion Of Cimzia®

* UCB AND FERRING PHARMACEUTICALS ANNOUNCE CO-PROMOTION OF CIMZIA® (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE